Wednesday, July 8, 2026

Drug profile · INN

ciprofloxacin

ciprofloxacin (APO-CIPROFLOXACIN) is a bacterial dna gyrase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 6
Pipeline programs 24
News articles 0
Drug details — ciprofloxacin
US status
approved
Class
Route
INJECTION
Patents
6
Programs
24
Data quality
0.89

Quick answer

ciprofloxacin (APO-CIPROFLOXACIN) is a bacterial dna gyrase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN ciprofloxacin
Brand APO-CIPROFLOXACIN
Mechanism Bacterial DNA gyrase inhibitor
Target Bacterial DNA gyrase
Route INJECTION
Formulation TABLET

Mechanism of action

Bacterial DNA gyrase inhibitor

Primary target: Bacterial DNA gyrase

Approval history

Authority Status Date
FDA approved
TGA approved

Pipeline programs

  1. 750 mg Imsidolimab Phase 3 · Vanda Pharmaceuticals Netherlands · Generalized Pustular Psoriasis
  2. APHP220763 Phase 3 · PARItec · Catheter related bloodstream infections due to Staphylococcu
  3. Ciprofloxacin (BAYQ3939) dry powder for inhalation Phase 3 · Bayer HealthCare Animal · Bronchiectasis
  4. Extended Release Buprenorphine Phase 3 · BRIGHT MINDS BIOSCIENCES · Substance Use Disorder
  5. Extended Release Naltrexone Phase 3 · BRIGHT MINDS BIOSCIENCES · Opioid Use Disorder
  6. Extended treatment Phase 3 · BRIGHT MINDS BIOSCIENCES · Nicotine Dependence
  7. M14-671 Phase 3 · AbbVie Deutschland GmbH · Crohn's Disease (CD)
  8. VACAB-2022 Phase 3 · George Institute for · Patients with hip or knee infections

Related & competitor drugs

  1. cinoxacin Bacterial DNA gyrase inhibitor
  2. ciprofloxacin hydrochloride Bacterial DNA gyrase inhibitor
  3. moxifloxacin hydrochloride Bacterial DNA gyrase inhibitor
  4. ofloxacin Bacterial DNA gyrase inhibitor
  5. alatrofloxacin mesylate Bacterial DNA gyrase inhibitor
  6. besifloxacin hydrochloride Bacterial DNA gyrase inhibitor
  1. US 12097185

    Compositions comprising ciprofloxacin and celecoxib

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11369566

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 9603796

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 9233068

    Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 9205048

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 8318817

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ciprofloxacin?

ciprofloxacin (APO-CIPROFLOXACIN) is a bacterial dna gyrase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for ciprofloxacin?

APO-CIPROFLOXACIN is a marketed brand name for ciprofloxacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ciprofloxacin?

ciprofloxacin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.